|Title:||Boostrix?: A reduced-dose acellular pertussis vaccine for use in adolescents and adults||Authors:||Li W.-C.
|Keywords:||Boostrix?; Bordetella pertussis; Seroepidemiology; Tdap||Issue Date:||2009||Journal Volume:||8||Journal Issue:||10||Start page/Pages:||1317-1327||Source:||Expert Review of Vaccines||Abstract:||
Pertussis remains a serious problem in many countries. Even in countries with high vaccine, coverage and a long vaccination history, pertussis outbreaks occur periodically. Rather than being a disease of young children, pertussis has shifted to affect adolescents and adults. Increased pertussis burden in adolescents and adults is the major source of severe infection for young infants. An effective vaccine is needed to control the spread of pertussis beyond preschool children. Boostrix? is a reduced-dose acellular pertussis vaccine with diphtheria and tetanus toxoids, and is designed for use in adolescents and adults. Current evidence suggests that Boostrix is immunogenic and well tolerated. The pertussis component of Boostrix has been shown to be efficacious in a large-scale Phase III trial. More than 50 countries have given permit to the use of Boostrix, and many of them formally recommend the use of Boostrix in adolescents and adults. Designed as a vaccine for adolescence and adults, Boostrix has a long way to go to achieve large-scale use in those target groups. Nevertheless, we expect that the advent of Boostrix will lead to a much better control of pertussis in the general population. ? 2009 Expert Reviews Ltd.
|ISSN:||1476-0584||DOI:||10.1586/erv.09.96||SDG/Keyword:||aluminum; antibiotic agent; diphtheria pertussis tetanus vaccine; acellular vaccine; diphtheria pertussis tetanus vaccine; adolescent; adult; Bordetella pertussis; cellular immunity; clinical trial; cost effectiveness analysis; disease severity; drug cost; drug efficacy; drug induced headache; drug safety; drug tolerability; drug use; erythema; fatigue; fever; gastrointestinal symptom; human; humoral immunity; immunization; immunogenicity; infection control; injection site reaction; irritability; nonhuman; pain; pertussis; prevalence; priority journal; recommended drug dose; review; side effect; swelling; unspecified side effect; child; cost benefit analysis; disease transmission; economics; immunology; infant; middle aged; pertussis; practice guideline; preschool child; Adolescent; Adult; Child; Child, Preschool; Cost-Benefit Analysis; Diphtheria-Tetanus-Pertussis Vaccine; Drug Costs; Humans; Immunization Schedule; Infant; Middle Aged; Practice Guidelines as Topic; Vaccines, Acellular; Whooping Cough; Young Adult
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.